Price$19.61-2.00 (-9.23%)
01:30 PM02:30 PM
News · 26 weeks37-50%
2026-01-182026-07-12
Mix1690d
- Insider8(50%)
- Other4(25%)
- SEC Filings4(25%)
Latest news
25 items- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- PRApollomics Regains Full Compliance with Nasdaq Listing RequirementsFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed. As previously reported, the Company was notified by the Nasda
- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- PRApollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in AsiaFOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintai
- INSIDERChief Financial Officer Lin Peter Kuan-How converted options into 10,000 units of CLASS A ORDINARY SHARES and covered exercise/tax liability with 3,588 units of CLASS A ORDINARY SHARES, increasing direct ownership by 40% to 22,312 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERChief Executive Officer Chen Hung-Wen converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 3% to 148,334 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERDirector Chu Yi-An converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERDirector Chen Hong-Jung converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 16% to 3,620 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERDirector Tsai Hsien-Shu converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERChief Operating Officer Chen Yi-Kuei converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 15,000 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERDirector Jan Chen-Huan converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- SECSEC Form EFFECT filed by Apollomics Inc.EFFECT - Apollomics Inc. (0001944885) (Filer)
- INSIDERDirector Huang Ya-Chi converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 100% to 1,000 units (SEC Form 4)4 - Apollomics Inc. (0001944885) (Issuer)
- SECAmendment: SEC Form F-3/A filed by Apollomics Inc.F-3/A - Apollomics Inc. (0001944885) (Filer)
- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- SECSEC Form 20-F filed by Apollomics Inc.20-F - Apollomics Inc. (0001944885) (Filer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chen Hong-Jung3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 4 filed by Lin Peter Kuan-How4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Jan Chen-Huan3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Tsai Hsien-Shu3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lin Peter Kuan-How3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chen Hung-Wen3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chu Yi-An3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chen Yi-Kuei3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Huang Ya-Chi3/A - Apollomics Inc. (0001944885) (Issuer)
APLM FAQ
4 questionsWhere does APLM stock trade?
Apollomics Inc. (APLM) is listed on NASDAQ.What sector and industry is APLM in?
Apollomics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to APLM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare APLM side-by-side with any of them on Quantisnow.How can I track APLM on Quantisnow?
Quantisnow aggregates Apollomics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APLM to receive live email and push alerts on every new disclosure.